Institute of Science, Nirma University, Ahmedabad, India.
Biomedical Parasitology and Nano-immunology Lab, Amity Institute of Microbial Technology, Amity University, NOIDA, Uttar Pradesh-201313, India.
Curr Drug Targets. 2018;19(16):1958-1967. doi: 10.2174/1389450119666180406113428.
The herbal plant extract of Enicostemma littorale is widely used to medicate and treat type II Diabetes. This extract in medicine has shown its value in reducing blood glucose & lipid levels, and improving the kidney functioning, lipid profile, controlling blood pressure and heart rate. The well characterized chemical components such as iridoid and secoiridoid glycosides are present in aqueous and ethanolic extracts of the plant. Swertiamarin, a secoiridoid glycoside, is identified as the lead compound that confers anti-hyperglycemic & anti-hyperlipidemic effects. The swertiamarin binds with one or more molecular targets to alter their expression and/or activity. The in silico, in vivo and in vitro studies have been carried out to uncover the underlying molecular mechanism of action of swertiamarin and its derivatives for showing the better anti-diabetic & anti-hyperlipidemic activities. In brief, the present review focuses on unraveling the information about molecular targets of swertiamarin. Our review will open new avenues to develop therapeutic approaches and drugs to treat diabetes and other inflammatory diseases.
海滨木巴戟的草药植物提取物被广泛用于治疗 II 型糖尿病。这种在医学上的提取物在降低血糖和血脂水平、改善肾功能、血脂谱、控制血压和心率方面显示出了它的价值。该植物的水提物和醇提物中都存在特征明确的化学物质，如环烯醚萜苷和裂环烯醚萜苷。裂环烯醚萜苷中的当药苦苷被鉴定为具有降血糖和降血脂作用的主要化合物。当药苦苷与一个或多个分子靶标结合，改变它们的表达和/或活性。已经进行了基于计算机的、体内和体外研究，以揭示当药苦苷及其衍生物的潜在作用机制，以显示更好的抗糖尿病和抗高血脂活性。简而言之，本综述重点阐述了关于当药苦苷的分子靶标的信息。我们的综述将为开发治疗糖尿病和其他炎症性疾病的治疗方法和药物开辟新途径。
